美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Genomics Immunology and Healthcare ETF

39.83

-0.1700-0.43%

盤後：39.830.00000.00%16:10 EDT

成交量：4.57萬

成交額：182.10萬

市值：2.71億

市盈率：- -

高：40.20

開：40.12

低：39.71

收：40.00

52周最高：41.49

52周最低：22.33

股本：680.00萬

流通股本：680.00萬

量比：0.49

換手率：0.67%

股息：0.28

股息率：0.70%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

美銀全球研究：將Moderna(MRNA.US)目標價從38美元上調至40美元。

Twist Bioscience Corp：第四季度營收預計約1.23億至1.24億美元

基因編輯的商業化：一款產品220萬美元，A股超20家概念股，但多數只賣工具

红星资本局

傑富瑞因索馬圖林面臨的競爭風險，將伊普森評級下調至「表現遜於大盤」

莫德納股價下跌，因諾如病毒疫苗試驗遭遇挫折

莫德納疫苗管線逐漸清晰，新藥前景牽動市場

更正-在等待美國就流感疫苗作出關鍵決定之際，Moderna的季度營收超出預期

Moderna第二季度每股收益-1.97美元，優於IBES預期的-2.08美元

Moderna(MRNA.US)盤前跌5.7%二季度營收略低於預期。

Moderna宣佈：mRNA-1403 III期中期分析未達早期成功統計標準，正籌備新增隊列招募

Moderna預期其第五款產品Mflusiva將於8月5日迎來PDUFA審批關鍵節點

今日關注要點——7月31日（星期五）

默克、惠康與一家全球衞生組織合作，共同研製埃博拉疫苗以用於臨床試驗

AbCellera Biologics獲2800萬美元預付款及里程碑付款與階梯式版税

AbCellera攜手福泰製藥，共同開發針對自身免疫疾病的多特異性T細胞接合器

歐盟批准Opzelura®（蘆可替尼）乳膏：首款無類固醇外用JAK抑制劑問世，專治成人中度特應性皮炎

藥企因塞特展現強勁商業化勢頭營收猛增38%並上調全年預期

环球市场播报

Incyte 與 CMS 達成和解後上調年度營收預期

美股異動 | CRISPR基因編輯公司Scribe Therapeutics(SCTX.US)登陸美股市場開盤後升逾59%

Revolution Medicines新藥Daraxonrasib獲FDA受理，用於既往治療過的轉移性胰腺癌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IDNA/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":39.83,"timestamp":1789761600000,"preClose":40,"halted":0,"volume":45673,"hourTrading":{"tag":"盘后","latestPrice":39.83,"preClose":39.83,"latestTime":"16:10 EDT","volume":6617,"amount":263555.11,"timestamp":1789762203995,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004250000000000043,"floatShares":6800000,"shares":6800000,"eps":0,"marketStatus":"盤後交易","change":-0.17,"latestTime":"09-18 16:31:01 EDT","open":40.12,"high":40.2,"low":39.7101,"amount":1821020,"amplitude":0.012248,"askPrice":45.56,"askSize":100,"bidPrice":36.44,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":40,"sharesOutstanding":5100000,"nav":38.722209,"aum":263311021.2,"dividendRate":0.00703,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.9,"preClose":40,"latestTime":"09:14 EDT","volume":25,"amount":1017.07,"timestamp":1789737274853,"change":0.9,"changeRate":0.0225,"amplitude":0.03025},"postHourTrading":{"tag":"盘后","latestPrice":39.83,"preClose":39.83,"latestTime":"16:10 EDT","volume":6617,"amount":263555.11,"timestamp":1789762203995,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.490286,"impliedVol":0.2131,"impliedVolPercentile":0.5458},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.490286,"shares":6800000,"dividePrice":0.28,"high":40.2,"amplitude":0.012248,"preClose":40,"low":39.7101,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":39.83,"eps":0,"divideRate":0.00703,"volume":45673,"delay":0,"ttmEps":0,"open":40.12,"prevYearClose":26.19,"prevWeekClose":38.06,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":38.06,"twentyDayClose":39.29,"sixtyDayClose":31.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656376004","title":"美銀全球研究：將Moderna(MRNA.US)目標價從38美元上調至40美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376004","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376004?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 20:14","pubTimestamp":1785759295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IDNA","BK4568","BK4551","BK4532","BK4533","BK4501","BK4548","MRNY","UUP","WDNA","BK4588","GNOM","BK4534","LGHT","UDN","BK4585","MRNX","BK4139","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172365141","title":"Twist Bioscience Corp：第四季度營收預計約1.23億至1.24億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172365141","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172365141?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:18","pubTimestamp":1785755887,"startTime":"0","endTime":"0","summary":"Twist Bioscience Corp 公布了其第四季度业绩展望。公司预计，该季度的总营收将介于约1.23亿美元至1.24亿美元之间。这一预期区间反映了公司对当前业务运营状况的评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TWST","BK4585","ARKG","BK4139","IDNA","WDNA","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037309","title":"基因編輯的商業化：一款產品220萬美元，A股超20家概念股，但多數只賣工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037309","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656037309?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 18:53","pubTimestamp":1785754410,"startTime":"0","endTime":"0","summary":"红星资本局8月3日消息，近日，一名6岁女童在接受基因编辑临床试验后死亡的事件，将“基因编辑”这项前沿技术推向公众视野。红星资本局注意到，近年来，基因编辑这一创新医疗技术在β-地中海贫血、镰状细胞贫血病等遗传性疾病治疗领域已有成熟应用，国外也有获批上市的药物。在国内，目前布局基因编辑疗法的主要为新兴的生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829926851.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829926851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399300","IDNA","KOMP","SYNB","NBDS","DTEC","159982","TARK","WDNA","BMED","FWD","XT","GNOM","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656325798","title":"傑富瑞因索馬圖林面臨的競爭風險，將伊普森評級下調至「表現遜於大盤」","url":"https://stock-news.laohu8.com/highlight/detail?id=2656325798","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656325798?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 15:01","pubTimestamp":1785740464,"startTime":"0","endTime":"0","summary":"BUZZ-杰富瑞因索马图林面临的竞争风险，将伊普森评级下调至“表现逊于大盘”8月3日-** 杰富瑞将法国制药公司伊普森的评级从“中性”下调至“表现逊于大盘”，理由是其Somatuline药物面临长期风险** 该券商预测，受仿制药竞争以及卡穆鲁斯公司带来的压力增大影响，Somatuline在2027年的销售额将下滑20%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4S4400GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009354923.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0002141913.USD","PTH","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","BK4139","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656956093","title":"莫德納股價下跌，因諾如病毒疫苗試驗遭遇挫折","url":"https://stock-news.laohu8.com/highlight/detail?id=2656956093","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656956093?lang=zh_tw&edition=fundamental","pubTime":"2026-08-01 02:27","pubTimestamp":1785522454,"startTime":"0","endTime":"0","summary":"BUZZ-莫德纳股价下跌，因诺如病毒疫苗试验遭遇挫折7月31日-** 疫苗制造商莫德纳（Moderna）MRNA.O的股价下跌约4%，至55.71美元** 该公司表示，在晚期临床试验的中期分析中，其诺如病毒候选疫苗未能达到早期成功的统计学基准 (link)** 由于符合研究主要目标的病例积累速度低于预期，Moderna将把诺如病毒疫苗试验延续至下一个流行季节** 多伦多道明 Cowen 分析师泰勒","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4S43X26E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","GNOM","BK4534","LGHT","MRNX","MRNY","BK4532","BK4588","BK4585","BK4548","IDNA","MRNA","BK4551","BK4501","BK4139","BK4568","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191889577","title":"莫德納疫苗管線逐漸清晰，新藥前景牽動市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1191889577","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191889577?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 21:59","pubTimestamp":1785506345,"startTime":"0","endTime":"0","summary":"莫德纳公布了第二季度财报，营收达1.45亿美元，较去年同期微增约2%。然而，摩根大通的分析师指出，该公司的新冠疫苗业务高度集中于下半年。“我们预计市场不会过分关注本季度的具体营收数字，”分析师在研究报告中写道。至于管线进展，其一款诺如病毒疫苗在正在进行的关键临床试验中未达预期。与此同时，莫德纳预计其新型季节性流感疫苗有望在8月5日获得批准。“这意味着莫德纳将迎来第五个获批产品，但我们认为，仅凭此尚不足以推动公司踏上全新发展轨道，”分析师们评论道。莫德纳股价当日上涨1%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","BK4139","BK4585","BK4588","BK4501","BK4551","MRNY","BK4548","WDNA","BK4534","MRNX","BK4568","BK4533","IDNA","MRNA","BK4532","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655638003","title":"更正-在等待美國就流感疫苗作出關鍵決定之際，Moderna的季度營收超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655638003","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655638003?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:18","pubTimestamp":1785496718,"startTime":"0","endTime":"0","summary":"更新版 3-更正-在等待美国就流感疫苗作出关键决定之际，Moderna的季度营收超出预期诺如病毒候选疫苗面临临床试验挫折FDA将于8月5日前就流感疫苗作出决定Co下调年度研发支出预期第7段和第13段新增图表及高管评论，第10段和第15段新增分析师评论Mariam Sunny/Christy Santhosh路透7月31日-莫德纳公司周五公布的第二季度营收超出华尔街预期，这得益于疫苗合作款项及其新冠疫苗的国际销售收入，而投资者正等待美国监管机构对其流感疫苗的关键决定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4T43X19F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU2433249047.HKD","RXL","IDNA","PAWZ","BK4588","LU1699723380.USD","LU0070302665.USD","LU2361045086.USD","LU0980610538.SGD","XLV","LU2125154935.USD","JDOC","IE0002141913.USD","IXJ","LU0823416689.USD","LU1066053197.SGD","TRUH","LU2112291526.USD","IHE","LU2491050071.SGD","LU0289739699.SGD","LGHT","BK4568","SG9999013999.USD","LU2023250504.SGD","MRNY","MRNA","LU2357627491.SGD","LU1035773651.USD","LU1093756168.USD","IYH","LU1571399168.USD","LU0320765646.SGD","LU0265550359.USD","LU0058720904.USD","LU1162221912.USD","PPH","FTXH","SG9999014575.USD","FHLC","MRK","VHT","LU1061106388.HKD","WDNA","MRNX","HRTS","BMED","GNOM","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191369993","title":"Moderna第二季度每股收益-1.97美元，優於IBES預期的-2.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191369993","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191369993?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:16","pubTimestamp":1785496607,"startTime":"0","endTime":"0","summary":"Moderna公布的2026年第二季度财报显示，公司净亏损达8亿美元，折合每股收益为-1.97美元。这一数字，相较于市场通过IBES调查所预估的-2.08美元，表现略胜一筹。季度数据源自该公司于7月31日发布的官方财务报告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","BK4532","BK4568","BK4585","BK4551","BK4588","BK4501","GNOM","BK4139","MRNA","MRNY","LGHT","BK4533","BK4548","IDNA","BK4534","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368109","title":"Moderna(MRNA.US)盤前跌5.7%二季度營收略低於預期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368109?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:04","pubTimestamp":1785495856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4534","LGHT","MRNX","BK4548","BK4568","BK4588","GNOM","BK4551","MRNY","MRNA","IDNA","BK4585","BK4532","BK4533","WDNA","BK4139","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113092299","title":"Moderna宣佈：mRNA-1403 III期中期分析未達早期成功統計標準，正籌備新增隊列招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1113092299","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113092299?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:02","pubTimestamp":1785495775,"startTime":"0","endTime":"0","summary":"Moderna公司披露，其mRNA-1403候选药物在III期临床试验的中期分析中，并未达到预设的早期成功统计阈值。这一结果意味着，该药物未能展现出足以支撑其提前获批的显著疗效。尽管如此，公司并未止步于此。Moderna目前正紧锣密鼓地筹备，计划增设一个额外的受试者队列，以期进一步评估该药物的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","BK4551","GNOM","IDNA","BK4532","MRNY","MRNA","BK4534","BK4501","BK4548","BK4585","BK4568","BK4139","LGHT","BK4588","MRNX","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145717315","title":"Moderna預期其第五款產品Mflusiva將於8月5日迎來PDUFA審批關鍵節點","url":"https://stock-news.laohu8.com/highlight/detail?id=1145717315","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145717315?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:02","pubTimestamp":1785495774,"startTime":"0","endTime":"0","summary":"Moderna公司近日释放积极信号，预计其第五款产品——针对Mflusiva的疗法，有望在今年8月5日的PDUFA日期获得监管批准。这一日期标志着FDA对该药物申请的最终审查期限，若顺利通关，将成为Moderna产品管线中的又一重要里程碑。目前，市场正密切关注这一审批进程，期待它为生物医药领域注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4585","BK4139","MRNX","BK4532","BK4533","BK4551","BK4588","LGHT","MRNA","BK4534","IDNA","BK4501","WDNA","GNOM","BK4548","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655800659","title":"今日關注要點——7月31日（星期五）","url":"https://stock-news.laohu8.com/highlight/detail?id=2655800659","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655800659?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 02:30","pubTimestamp":1785436236,"startTime":"0","endTime":"0","summary":"今日关注要点——7月31日（星期五）《今日要闻》是一份通过电子邮件和PDF形式发布的刊物，内容涵盖当日主要新闻、事件、分析及其他专题报导。消费品制造商Church & Dwight则预计受需求疲软影响，第二季度营收将出现下滑。投资者将关注其新冠疫苗的销售情况，以及全年利润预期的任何调整。在加拿大经济方面，加拿大统计局计划发布5月份国内生产总值数据，预计将增长0.2%，此前为增长0.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL4T43W2IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","BK4581","IDNA","LU2237438978.USD","LU0878866978.SGD","BK4592","BEN","FENY","IXC","LBO","TEXU","GXPE","XOMX","AAUM","LGHT","VDE","WEEI","XOMO","LU1074936037.SGD","LU2430703095.HKD","CL","LU0266013472.USD","LU0971096721.USD","SG9999002224.SGD","TRUN","LU0690374615.EUR","MRNX","MRNY","DIG","CHD","IYE","ARES","LU1066053197.SGD","PRVT","IE00B1XK9C88.USD","GNOM","FTXN","DRLL","GPZ","LU2430703251.USD","MRNA","CVX","XLE","XOM","ERX","IGE","OILT","IE00BLSP4452.SGD","LU1496350171.SGD","XOMZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655842772","title":"默克、惠康與一家全球衞生組織合作，共同研製埃博拉疫苗以用於臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2655842772","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655842772?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 13:03","pubTimestamp":1785387832,"startTime":"0","endTime":"0","summary":"默克与惠康基金会的合作将推动国际艾滋病疫苗倡议组织研发的单剂量疫苗的生产，世界卫生组织今年5月曾将其列为最具前景的候选疫苗。希勒曼公司将利用IAVI提供的起始原料，生产可用于早期临床试验的成品疫苗剂量。默克公司传染病与疫苗研发负责人塔里特·穆科帕迪亚在接受采访时表示，疫苗剂量有望在今年年底前准备就绪，用于临床试验。穆科帕迪亚表示，希勒曼实验室具备生产数万剂疫苗的能力，这应足以满足试验需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL4S43W0CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0234572021.USD","BMED","LU1066051498.USD","IXJ","LU1989772923.USD","LU1934455277.USD","SG9999014575.USD","BK4550","IDNA","XLV","LU1291159041.SGD","LU1430594728.SGD","LU2491050071.SGD","LU2361045086.USD","IE00B2B36J28.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","SG9999014559.SGD","LU1974910355.USD","LU0965509010.AUD","IE00BBT3K403.USD","LU1923622614.USD","RXL","LU0266013472.USD","IHE","IE00BLSP4452.SGD","IE0002141913.USD","LU0648001328.SGD","LU0689626769.HKD","MRK","BK4585","LU0211331839.USD","BK4007","IE00B1BXHZ80.USD","SG9999014542.SGD","VHT","LU0058720904.USD","LU1983299246.USD","LU0432979614.USD","LU2360032135.SGD","LU0203347892.USD","BK4534","LGHT","BK4516","LU2361044949.HKD","HRTS","LU0265550946.USD","LU1989771016.USD","LU1069347547.HKD","BK4568","PAWZ","BK4501","LU0203345920.USD","MRNX","LU1917777945.USD","IE00BLSP4239.USD","IE00B4R5TH58.HKD","LU0006306889.USD","LU0320765646.SGD","LU1023059063.AUD","LU0208291251.USD","LU1699723380.USD","LU0868494708.USD","LU0942090050.USD","GDOC","LU2125909247.SGD","LU1201861249.SGD","JDOC","BK4548","BK4551","LU1066053197.SGD","IE00BN8TJ469.HKD","LU0124676726.USD","BK4559","BK4588","LU2491050154.USD","LU0070302665.USD","SG9999001176.USD","LU1941712264.USD","SG9999013999.USD","LU1116320901.HKD","LU0868494617.USD","LU1934455194.USD","LU1162221912.USD","LU0980610538.SGD","LU1035773651.USD","LU2491049909.HKD","PPH","IE000M9KFDE8.USD","LU2125154935.USD","LU1934455863.HKD","LU0965509101.SGD","LU2125909593.SGD","SG9999002232.USD","LU0106261372.USD","LU1929549753.HKD","LU0130517989.USD","SG9999002224.SGD","BK4532","LU2468319806.SGD","IE00BSNM7G36.USD","GNOM","BK4533","IE0009355771.USD","LU0477156953.USD","LU1061106388.HKD","LU1093756325.SGD","LU2125154778.USD","LU0861579265.USD","LU1093756168.USD","LU2112291526.USD","LU1066051225.USD","LU0238689110.USD","LU1116320737.USD","WDNA","FTXH","LU1057294990.SGD","LU0985320562.USD","LU2324357040.USD","SGXZ57979304.SGD","IE00BJJMRZ35.SGD","LU0265550359.USD","SG9999015341.SGD","LU1571399168.USD","LU0098860793.USD","LU1037948897.HKD","MRNY","FHLC","LU0859254822.USD","LU0965509283.SGD","LU2023250843.SGD","LU1037948541.HKD","LU2433249047.HKD","LU0122379950.USD","LU1989772840.SGD","TRUH","SG9999001440.SGD","LU2023250504.SGD","LU2361044865.SGD","IE00BJT1NW94.SGD","IYH","SG9999001176.SGD","LU2106854487.HKD","LU2461242641.AUD","LU2089984988.USD","MRNA","LU2357627491.SGD","SG9999014567.USD","LU0320765489.SGD","LU0130102774.USD","LU1941712348.USD","LU1066051811.HKD","SG9999015358.SGD","LU0965508806.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics獲2800萬美元預付款及里程碑付款與階梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185330982?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU1674673428.USD","LU2324357040.USD","SG9999013999.USD","LU0417517546.SGD","LU1035775433.USD","SG9999001176.SGD","IBBQ","LU2237438978.USD","SG9999001176.USD","IE00B4R5TH58.HKD","LU2236285917.USD","BIB","IE00B19Z9P08.USD","LU2362540622.SGD","PBE","BK4588","BK4535","BK4139","LU2462157665.USD","BK4567","LU0079474960.USD","BBH","BK4532","IE00B894F039.SGD","LU0058720904.USD","LU0061475181.USD","LU0889565916.HKD","LU1069344957.HKD","IE00B19Z3581.USD","LU1585245621.USD","VRTX","LU2362541273.HKD","GNMX","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","IE0002270589.USD","LU0823416689.USD","TBXU","IE00BZ9MQY76.HKD","LU2417539215.USD","LU0109394709.USD","SGXZ57979304.SGD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU1674673691.USD","ABCL","LU0289739699.SGD","BK4121","LU1093756325.SGD","BK4585","LU2456880835.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","IE00B2B36J28.USD","LU0256863811.USD","LU1093756168.USD","IE00B19Z9Z06.USD","LU2362541513.USD","LU1778281490.HKD","IDNA","IE0002141913.USD","IE0009355771.USD","LU0320765992.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera攜手福泰製藥，共同開發針對自身免疫疾病的多特異性T細胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147206442?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作，旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势，致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU1674673428.USD","LU0058720904.USD","IDNA","IE00B894F039.SGD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","LU2462157665.USD","LU1093756325.SGD","TBXU","BK4567","LU1069344957.HKD","BIB","SG9999001176.USD","VRTX","BK4532","LU2324357040.USD","SG9999013999.USD","IE00BJT1NW94.SGD","LU0432979614.USD","LU2456880835.USD","LU0061475181.USD","LU0256863811.USD","LU1430594728.SGD","BK4588","LU2362541273.HKD","ABCL","LU2362541513.USD","SG9999001176.SGD","BK4121","LU1778281490.HKD","GNMX","LU2362540622.SGD","LU0417517546.SGD","LU1093756168.USD","IE00B19Z3B42.SGD","LU2237438978.USD","IE0009355771.USD","LU0079474960.USD","SGXZ57979304.SGD","LU1674673691.USD","LU0289739699.SGD","BBH","LU0889565916.HKD","LU1035775433.USD","IE00B19Z9Z06.USD","BK4533","IE0002270589.USD","IE00B19Z9P08.USD","LU0109394709.USD","LU1585245621.USD","LU0823416689.USD","IE00B2B36J28.USD","LU2417539215.USD","PBE","IBBQ","BK4139","LU2236285917.USD","IE0002141913.USD","BK4585","BK4535","IE00BFTCPJ56.SGD","LU0320765992.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170637857","title":"歐盟批准Opzelura®（蘆可替尼）乳膏：首款無類固醇外用JAK抑制劑問世，專治成人中度特應性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1170637857","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170637857?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:01","pubTimestamp":1785319274,"startTime":"0","endTime":"0","summary":"重大突破！欧盟正式批准Opzelura®（芦可替尼）乳膏上市。这款无类固醇外用JAK抑制剂，成为该地区首款用于成人中度特应性皮炎患者的同类创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","IDNA","INCY","BK4550","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655691882","title":"藥企因塞特展現強勁商業化勢頭 營收猛增38%並上調全年預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655691882","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655691882?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 03:15","pubTimestamp":1785266100,"startTime":"0","endTime":"0","summary":"生物制药公司因塞特周二公布的第二季度财报显示，得益于核心产品的全面增长以及与政府就Opzelura返款纠纷达成和解带来的一次性收益，公司营收大幅超出预期，并上调了全年业绩指引。财报显示，因塞特第二季度总营收达16.7亿美元，同比增长38%。核心产品表现方面，旗舰产品Jakafi及其新剂型Jakafi XR的季度销售额为8.17亿美元，同比增长7%。Opzelura销售表现尤为强劲，季度净销售额达4.50亿美元，同比飙升173%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-29/doc-inikkxfz6152612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","IDNA","BK4139","BK4588","INCY","BK4532","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002254","title":"Incyte 與 CMS 達成和解後上調年度營收預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002254","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002254?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 20:58","pubTimestamp":1785243519,"startTime":"0","endTime":"0","summary":"Incyte 与 CMS 达成和解后上调年度营收预期路透7月28日-制药公司Incyte Corp周二公布第二季度盈利增长，并上调了年度营收预期。Incyte 于 6 月就其湿疹和白癜风治疗药物 Opzelura 的回扣标准，与美国医疗保险和医疗补助服务中心达成和解。CMS同意不将Opzelura归类为Incyte公司老药Jakafi的产品线延伸，而该公司则同意撤回对其相关法规提出质疑的诉讼。Incyte还表示，已停止针对血液癌症的INCB160058药物的进一步研发，并将优先推进其下一代疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL4T43U1IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4550","IDNA","INCY","BK4139","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036699","title":"美股異動 | CRISPR基因編輯公司Scribe Therapeutics(SCTX.US)登陸美股市場 開盤後升逾59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036699?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1861558580.USD","FWD","HELX","ARKG","KOMP","BK4539","CRSP","IDNA","LU1861559042.SGD","LENZ","XT","BK4585","BMED","BK4588","TARK","BK4007","DTEC","GNOM","BK4556","SCTX","NBDS","BK4139","SYNB","WDNA","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178535518","title":"Revolution Medicines新藥Daraxonrasib獲FDA受理，用於既往治療過的轉移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1178535518","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178535518?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 04:06","pubTimestamp":1784750800,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理Revolution Medicines, Inc.提交的新药上市申请（NDA），该申请旨在寻求批准其候选药物Daraxonrasib用于治疗既往接受过治疗的转移性胰腺癌患者。\n这一受理标志着该药物研发进程中的一个关键监管里程碑，意味着FDA已认定申请材料完整，并已启动实质性的审评流程。胰腺癌，尤其是转移性疾病，长期以来预后不佳，治疗选择有限，因此这一新疗法的审评进展备受业界关注。\n公司股价在消息公布后反应积极，市场正密切关注后续的审评时间表以及可能的批准前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","IE00BFTCPJ56.SGD","BK4139","BBH","LU0320765992.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0109394709.USD","PTH","RVMD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IDNA","IE0009355771.USD","CANC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}